Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Vernon Holers to Binding Sites

This is a "connection" page, showing publications Vernon Holers has written about Binding Sites.

 
Connection Strength
 
 
 
0.597
 
  1. Hannan JP, Laskowski J, Thurman JM, Hageman GS, Holers VM. Mapping the Complement Factor H-Related Protein 1 (CFHR1):C3b/C3d Interactions. PLoS One. 2016; 11(11):e0166200.
    View in: PubMed
    Score: 0.110
  2. Kovacs JM, Hannan JP, Eisenmesser EZ, Holers VM. Biophysical investigations of complement receptor 2 (CD21 and CR2)-ligand interactions reveal amino acid contacts unique to each receptor-ligand pair. J Biol Chem. 2010 Aug 27; 285(35):27251-27258.
    View in: PubMed
    Score: 0.071
  3. Kovacs JM, Hannan JP, Eisenmesser EZ, Holers VM. Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis. J Biol Chem. 2009 Apr 03; 284(14):9513-20.
    View in: PubMed
    Score: 0.064
  4. Hannan JP, Young KA, Guthridge JM, Asokan R, Szakonyi G, Chen XS, Holers VM. Mutational analysis of the complement receptor type 2 (CR2/CD21)-C3d interaction reveals a putative charged SCR1 binding site for C3d. J Mol Biol. 2005 Feb 25; 346(3):845-58.
    View in: PubMed
    Score: 0.048
  5. Guthridge JM, Young K, Gipson MG, Sarrias MR, Szakonyi G, Chen XS, Malaspina A, Donoghue E, James JA, Lambris JD, Moir SA, Perkins SJ, Holers VM. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface. J Immunol. 2001 Nov 15; 167(10):5758-66.
    View in: PubMed
    Score: 0.039
  6. Makar KW, Ulgiati D, Hagman J, Holers VM. A site in the complement receptor 2 (CR2/CD21) silencer is necessary for lineage specific transcriptional regulation. Int Immunol. 2001 May; 13(5):657-64.
    View in: PubMed
    Score: 0.038
  7. Takahashi K, Banda NK, Holers VM, Van Cott EM. Complement component factor B has thrombin-like activity. Biochem Biophys Res Commun. 2021 05 07; 552:17-22.
    View in: PubMed
    Score: 0.037
  8. Makar KW, Pham CT, Dehoff MH, O'Connor SM, Jacobi SM, Holers VM. An intronic silencer regulates B lymphocyte cell- and stage-specific expression of the human complement receptor type 2 (CR2, CD21) gene. J Immunol. 1998 Feb 01; 160(3):1268-78.
    View in: PubMed
    Score: 0.030
  9. Molina H, Kinoshita T, Webster CB, Holers VM. Analysis of C3b/C3d binding sites and factor I cofactor regions within mouse complement receptors 1 and 2. J Immunol. 1994 Jul 15; 153(2):789-95.
    View in: PubMed
    Score: 0.023
  10. Li K, Gor J, Holers VM, Storek MJ, Perkins SJ. Solution structure of TT30, a novel complement therapeutic agent, provides insight into its joint binding to complement C3b and C3d. J Mol Biol. 2012 May 04; 418(3-4):248-63.
    View in: PubMed
    Score: 0.020
  11. Molina H, Brenner C, Jacobi S, Gorka J, Carel JC, Kinoshita T, Holers VM. Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction. J Biol Chem. 1991 Jul 05; 266(19):12173-9.
    View in: PubMed
    Score: 0.019
  12. Shaw CD, Storek MJ, Young KA, Kovacs JM, Thurman JM, Holers VM, Hannan JP. Delineation of the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular docking. J Mol Biol. 2010 Dec 10; 404(4):697-710.
    View in: PubMed
    Score: 0.018
  13. Holers VM. Complement receptors. Year Immunol. 1989; 4:231-40.
    View in: PubMed
    Score: 0.016
  14. Young KA, Herbert AP, Barlow PN, Holers VM, Hannan JP. Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350. J Virol. 2008 Nov; 82(22):11217-27.
    View in: PubMed
    Score: 0.016
  15. Song H, Qiao F, Atkinson C, Holers VM, Tomlinson S. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J Immunol. 2007 Dec 01; 179(11):7860-7.
    View in: PubMed
    Score: 0.015
  16. Young KA, Chen XS, Holers VM, Hannan JP. Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21). J Biol Chem. 2007 Dec 14; 282(50):36614-25.
    View in: PubMed
    Score: 0.015
  17. Hibbert RG, Teriete P, Grundy GJ, Beavil RL, Reljic R, Holers VM, Hannan JP, Sutton BJ, Gould HJ, McDonnell JM. The structure of human CD23 and its interactions with IgE and CD21. J Exp Med. 2005 Sep 19; 202(6):751-60.
    View in: PubMed
    Score: 0.013
  18. Aubry JP, Pochon S, Gauchat JF, Nueda-Marin A, Holers VM, Graber P, Siegfried C, Bonnefoy JY. CD23 interacts with a new functional extracytoplasmic domain involving N-linked oligosaccharides on CD21. J Immunol. 1994 Jun 15; 152(12):5806-13.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)